405 related articles for article (PubMed ID: 31486267)
1. Extreme hypofractionated proton radiotherapy for prostate cancer using pencil beam scanning: Dosimetry, acute toxicity and preliminary results.
Kubeš J; Vondráček V; Andrlik M; Navrátil M; Sláviková S; Vítek P; Rosina J; Abrahámová J; Prausová J; Grebenyuk A; Dědečková K
J Med Imaging Radiat Oncol; 2019 Dec; 63(6):829-835. PubMed ID: 31486267
[TBL] [Abstract][Full Text] [Related]
2. Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes.
Kubeš J; Haas A; Vondráček V; Andrlík M; Navrátil M; Sláviková S; Vítek P; Dědečková K; Prausová J; Ondrová B; Vinakurau Š; Grebenyuk A; Doležal T; Velacková B; Rosina J
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1090-1097. PubMed ID: 33587990
[TBL] [Abstract][Full Text] [Related]
3. 5-Years Analysis of Effectivity and Toxicity of Ultra-Hypofractionated Proton Radiotherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer-A Retrospective Analysis.
Kubeš J; Sláviková S; Vítek P; Haas A; Ondrová B; Dedečková K; Andrlík M; Domanský M; Jiránková K; Schlencová V; Harazimová A; Turková B; Doležal T; Al-Hamami SFA; Vondráček V
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760540
[TBL] [Abstract][Full Text] [Related]
4. Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer.
Choo R; Hillman DW; Mitchell C; Daniels T; Vargas C; Rwigema JC; Corbin K; Keole S; Vora S; Merrell K; Stish B; Pisansky T; Davis BJ; Amundson A; Wong W
Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1085-1094. PubMed ID: 36427645
[TBL] [Abstract][Full Text] [Related]
5. High efficacy of hypofractionated proton therapy with 4 fractions of 5 Gy as a boost to 50 Gy photon therapy for localized prostate cancer.
Johansson S; Isacsson U; Sandin F; Turesson I
Radiother Oncol; 2019 Dec; 141():164-173. PubMed ID: 31431382
[TBL] [Abstract][Full Text] [Related]
6. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer.
Grewal AS; Schonewolf C; Min EJ; Chao HH; Both S; Lam S; Mazzoni S; Bekelman J; Christodouleas J; Vapiwala N
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):713-722. PubMed ID: 31199994
[TBL] [Abstract][Full Text] [Related]
7. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
9. A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients.
Vapiwala N; Wong JK; Handorf E; Paly J; Grewal A; Tendulkar R; Godfrey D; Carpenter D; Mendenhall NP; Henderson RH; Stish BJ; Vargas C; Salama JK; Davis BJ; Horwitz EM
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1082-1089. PubMed ID: 33539968
[TBL] [Abstract][Full Text] [Related]
10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
11. Minimal toxicity after proton beam therapy for prostate and pelvic nodal irradiation: results from the proton collaborative group REG001-09 trial.
Chuong MD; Hartsell W; Larson G; Tsai H; Laramore GE; Rossi CJ; Wilkinson JB; Kaiser A; Vargas C
Acta Oncol; 2018 Mar; 57(3):368-374. PubMed ID: 29034790
[TBL] [Abstract][Full Text] [Related]
12. Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
Matta R; Chapple CR; Fisch M; Heidenreich A; Herschorn S; Kodama RT; Koontz BF; Murphy DG; Nguyen PL; Nam RK
Eur Urol; 2019 Mar; 75(3):464-476. PubMed ID: 30573316
[TBL] [Abstract][Full Text] [Related]
13. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
[TBL] [Abstract][Full Text] [Related]
14. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
Deville C; Jain A; Hwang WT; Woodhouse KD; Both S; Wang S; Gabriel PE; Christodouleas JP; Bekelman J; Tochner Z; Vapiwala N
Acta Oncol; 2018 Nov; 57(11):1506-1514. PubMed ID: 30028227
[TBL] [Abstract][Full Text] [Related]
15. Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: side effects preliminary analysis of a phase II trial.
Gregucci F; Carbonara R; Surgo A; Ciliberti MP; Curci D; Ciocia A; Branà L; Ludovico GM; Scarcia M; Portoghese F; Caliandro M; Ludovico E; Paulicelli E; Di Guglielmo FC; Bonaparte I; Fiorentino A
Radiol Med; 2023 Apr; 128(4):501-508. PubMed ID: 36952115
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
17. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
18. Moderate hypofractionated post-prostatectomy radiation therapy is feasible and well tolerated: experience from a single tertiary cancer centre.
Valero J; Montero A; Hernando O; Izquierdo M; Sánchez E; García-Aranda M; López M; Ciérvide R; Martí J; Álvarez B; Alonso R; Chen-Zhao X; Fernández-Letón P; Rubio C
Clin Transl Oncol; 2021 Jul; 23(7):1452-1462. PubMed ID: 33433839
[TBL] [Abstract][Full Text] [Related]
19. Post-operative hypofractionated radiotherapy for prostate cancer: a mono-institutional analysis of toxicity and clinical outcomes.
Ferrera G; D'Alessandro S; Cuccia F; Serretta V; Trapani G; Savoca G; Mortellaro G; Lo Casto A
J Cancer Res Clin Oncol; 2022 Jan; 148(1):89-95. PubMed ID: 34595542
[TBL] [Abstract][Full Text] [Related]
20. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
